Is the Combination of Pharmacokinetic and Pharmacodynamic Monitoring of Infliximab-Treated Patients the Way Forward?

Clin Gastroenterol Hepatol. 2020 Oct;18(11):2631-2632. doi: 10.1016/j.cgh.2020.02.029. Epub 2020 Feb 21.

Authors

Natália Sousa Freitas Queiroz¹, Aline Charabaty²

Affiliations

¹ Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo, Brazil.
² Johns Hopkins School of Medicine, Washington, District of Columbia.

PMID: 32092397
DOI: 10.1016/j.cgh.2020.02.029

No abstract available

Publication types

Letter
Comment

MeSH terms

Crohn Disease* / drug therapy
Drug Monitoring
Gastrointestinal Agents / therapeutic use
Humans
Infliximab / therapeutic use
Leukocyte L1 Antigen Complex

Substances

Gastrointestinal Agents
Leukocyte L1 Antigen Complex
Infliximab